Google
Trusted Resources: News & Events
Latest announcements and gatherings
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCD
The Green Park Collaborative (GPC) is working with the Sickle Cell Disease Association of America (SCDAA) to develop a consensus of desired outcomes to be used in clinical studies evaluating new treatments for sickle cell disease (SCD).
The project, named coreSCD, aims to deliver a list of recommendations on the best outcomes to address the effectiveness and safety of potential therapies for SCD in clinical trials.
Multiple parties will be involved in the initiative, including patients and their families, clinicians, companies developing new SCD therapies, regulators (e.g., the U.S. Food and Drug Administration (FDA), healthcare payers (e.g., private healthcare plans and Medicaid), and sponsors from industry and academia.
One of the project leaders, the Green Park Collaborative (GPC), is a multi-stakeholder forum dedicated to creating disease and technology-specific recommendations to guide the production of evidence to inform both clinical and payment decisions. The forum will be a collaboration of a broad group of national and international partners.
+myBinderRelated Content
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseBackground: Deoxygenated sickle hemog...
-
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive EventsBACKGROUND: Sickle cell anemia is an inh...
-
Kids With Sickle Cell Anemia are More Sedentary Than Healthy Peers, Study SuggestsChildren and adolescents with sickle cel...
-
Sickle Cell Groups, Pfizer Work to Bring African-Americans into Clinical TrialsIt’s been nearly half a century since ...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.